Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

David Becton to Infant

This is a "connection" page, showing publications David Becton has written about Infant.

 
Connection Strength
  
 
 
0.223
  
  1. Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol. 2007 Apr; 29(4):216-21.
    View in: PubMed
    Score: 0.040
  2. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 2006 Feb 15; 107(4):1315-24.
    View in: PubMed
    Score: 0.036
  3. Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4.
    View in: PubMed
    Score: 0.033
  4. Stine KC, Saylors RL, Saccente S, Becton DL. Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate. Med Pediatr Oncol. 2003 Jul; 41(1):77-8.
    View in: PubMed
    Score: 0.031
  5. Mack JM, Richter GT, Becton D, Salem O, Hill SEM, Crary SE. Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations. Pediatr Blood Cancer. 2018 06; 65(6):e27008.
    View in: PubMed
    Score: 0.021
  6. Mian A, Becton D, Saylors R, James L, Tang X, Bhutta A, Prodhan P. Biomarkers for risk stratification of febrile neutropenia among children with malignancy: a pilot study. Pediatr Blood Cancer. 2012 Aug; 59(2):238-45.
    View in: PubMed
    Score: 0.014
  7. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010 Mar 25; 115(12):2372-9.
    View in: PubMed
    Score: 0.012
  8. Mian A, Becton D, Blackall DP, James SH, Berman DM, Owusu JA, Turner C, Givner LB, Shetty AK. Index of suspicion. Pediatr Rev. 2009 Apr; 30(4):139-45.
    View in: PubMed
    Score: 0.011
  9. Savasan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma. 2006 Oct; 47(10):2076-83.
    View in: PubMed
    Score: 0.010
  10. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood. 2004 Nov 01; 104(9):2646-54.
    View in: PubMed
    Score: 0.008
  11. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol. 2002 Mar 15; 20(6):1617-24.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.